Welcome to our dedicated page for integ news (Ticker: integ), a resource for investors and traders seeking the latest updates and insights on integ stock.
Integrum (publ) is a pioneering medical technology company based in Sweden, listed on NASDAQ First North Growth Market under the symbol INTEG. The company specializes in the development and commercialization of the OPRA™ Implant System, a groundbreaking solution for amputees. Recently, Integrum secured full funding from the US Department of Defense to conduct a clinical study on transtibial amputations at the Walter Reed National Military Medical Center. This study, once completed, will provide valuable data for future regulatory processes and expansion of the OPRA™ Implant System. Led by CEO Rickard Brånemark, Integrum is dedicated to revolutionizing amputee care and improving the lives of individuals worldwide.
Integrum AB (Nasdaq First North: INTEG B) has announced a new compensation package for Board Director and Acting CEO Scott Flora, focusing on performance-based incentives during the company's strategic transition. The package includes 200,000 Stock Appreciation Rights (SARs) with a maximum compensation of SEK 60 per SAR and a base price of SEK 29.30.
The SARs will vest at a rate of 20% every three months starting June 1, 2025, and can be exercised between September 1-October 31, 2026. Unvested SARs will lapse without payment. The company maintains flexibility to pay in either stock or cash. As part of this restructuring, Flora's fixed compensation will be reduced. This adjustment aligns with the company's executive compensation guidelines approved at the latest shareholders' meeting.
Integrum AB (INTEG B) has announced compelling results from a two-year follow-up study conducted by Walter Reed National Military Medical Center on their OPRA™ Implant System for transfemoral amputees. The Level II Evidence study, focusing on the latest version introduced in 2017, demonstrates significant advantages over traditional socket prostheses.
The study revealed several key achievements:
- 100% implant survival rate
- Reduced infection and complication rates compared to previous data
- Increased prosthetic use
- Improved mobility and quality of life for patients
The research, published in Clinical Orthopaedics and Related Research (CORR), was conducted by a team led by Dr. Benjamin K. Potter and Dr. Jonathan Forsberg. The findings are expected to drive further adoption among US health providers and potentially increase insurance provider reimbursement coverage.